# ABL Bio Unveils Cancer Antibody Data at ESMO

> ABL Bio shows clinical results for two cancer-targeting antibodies at ESMO conference.
- Title: ABL Bio Unveils Cancer Antibody Data at ESMO · BigGo Finance
- Summary: ABL Bio shows clinical results for two cancer-targeting antibodies at ESMO conference. ABL Bio presents Phase 2 and Phase 1 data for bispecific antibodies…
- Keywords: abl bio, zivastomig, razastomig, esmo, 4-1bb, gastroesophageal cancer, nivolumab, fda fast-track, orphan drug, finance, markets, ABL
- Source: BigGo Finance — https://finance.biggo.com/news/9c3d8ecc-cf96-4811-83b4-8f8159cce8ec
- Author: BigGo Finance
- Published: 2026-10-19T01:55:49+00:00
- Read time: 1 min
- Topics: abl bio, zivastomig, razastomig, esmo, 4-1bb, gastroesophageal cancer, nivolumab, fda fast-track, orphan drug, finance, markets
## Zivastomig Clinical Data
ABL Bio will present clinical data for Zivastomig (ABL111) at ESMO.

> Zivastomig simultaneously targets claudin 18.2 and 4-1bb
## Zivastomig Phase 2 Trial
Zivastomig targets Claudin 18.2 and 4-1BB for metastatic gastroesophageal cancer.

> It has received fda fast-track and orphan drug designations
## Zivastomig FDA Status
Zivastomig has FDA fast-track and orphan drug designations for gastroesophageal cancer.

> It has received fda fast-track and orphan drug designations
## Razastomig Clinical Data
ABL Bio will present Razastomig (ABL503) data at ESMO.

> Razastomig targets pd-l1 and 4-1bb
## Razastomig Phase 1 Trial
Razastomig is in Phase 1 for monotherapy dose optimization.

> Phase 1 data related to dose optimization of the monotherapy will be released
## ESMO Presentation Dates
Zivastomig data released October 25; Razastomig data released October 23.

> The presentation scheduled for october 25
## Key takeaway

ABL Bio presents Phase 2 and Phase 1 data for bispecific antibodies targeting gastroesophageal cancer at ESMO.